Brief: Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU
May 22 (Reuters) - BioArctic AB BIOAb.ST: BIOARCTIC RECEIVES POSITIVE OPINION FOR ORPHAN MEDICINAL PRODUCT DESIGNATION IN THE EU FOR EXIDAVNEMAB IN MULTIPLE SYSTEM ATROPHY Source text: ID:nWkr7g9xFr Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million